Recursion Pharmaceuticals Inc - ESG Rating & Company Profile powered by AI
This webpage displays a zero-cost Sustainability assessment for Recursion Pharmaceuticals Inc. Other companies in the rating industry group for Recursion Pharmaceuticals Inc are shown below. The report of Recursion Pharmaceuticals Inc incorporates information from across the web and also from available disclosures by Recursion Pharmaceuticals Inc.
Recursion Pharmaceuticals Inc in the Pharmaceuticals industry gained a UN SDG ESG Transparency Score of 3.7; made up of an environmental score of 1.3, social score of 5.7 and governance score of 4.0.
3.7
Low ImpactEnvironmental
Social
Governance

Peer Group Comparison
Rank | Company | SDG Transparency Score ⓘ | Performance |
---|---|---|---|
1 | Caladrius Biosciences Inc | 8.0 | High |
1 | Can Fite Biopharma Ltd | 8.0 | High |
... | ... | ... | |
1112 | XSpray Pharma AB (publ) | 3.8 | Medium |
1112 | Zhongzhi Pharmaceutical Holdings Ltd | 3.8 | Medium |
1132 | Recursion Pharmaceuticals Inc | 3.7 | Medium |
1132 | Chemometec A/S | 3.7 | Medium |
1132 | BEACON Pharmaceutical Ltd | 3.7 | Medium |
... | ... | ... | |
1970 | Zyden Gentec Ltd | 0.0 | Low |
1970 | iNtRON Biotechnology Inc | 0.0 | Low |
... | ... | ... |

Frequently Asked Questions
Does Recursion Pharmaceuticals Inc have an accelerator or VC vehicle to help deliver innovation?
Does Recursion Pharmaceuticals Inc disclose current and historical energy intensity?
Does Recursion Pharmaceuticals Inc report the average age of the workforce?
Does Recursion Pharmaceuticals Inc reference operational or capital allocation in relation to climate change?
Does Recursion Pharmaceuticals Inc disclose its ethnicity pay gap?
Does Recursion Pharmaceuticals Inc disclose cybersecurity risks?
Does Recursion Pharmaceuticals Inc offer flexible work?
Does Recursion Pharmaceuticals Inc have a long term incentive (LTI) executive compensation plan based on a measure of return on capital?
Does Recursion Pharmaceuticals Inc disclose the number of employees in R&D functions?
Does Recursion Pharmaceuticals Inc conduct supply chain audits?
Does Recursion Pharmaceuticals Inc disclose incidents of non-compliance in relation to the health and safety impacts of products and services?
Is there a statment that there is no plan to expand their cement production? (for example: 'We have no current plans to add additional cement making capacity')
Does Recursion Pharmaceuticals Inc conduct 360 degree staff reviews?
Does Recursion Pharmaceuticals Inc disclose the individual responsible for D&I?
Does Recursion Pharmaceuticals Inc disclose current and historical air emissions?
Is there a statment that there is no plan to expand their coal usage? (for example: 'We have no current plans to add additional coal powered electricity generation')
Is executive remuneration linked to climate performance?
Does the Board describe its role in the oversight of climate-related risks and opportunities?
Does Recursion Pharmaceuticals Inc disclose current and / or historical scope 2 emissions?
Does Recursion Pharmaceuticals Inc disclose water use targets?
Does Recursion Pharmaceuticals Inc have careers partnerships with academic institutions?
Did Recursion Pharmaceuticals Inc have a product recall in the last two years?
Does Recursion Pharmaceuticals Inc disclose incidents of discrimination?
Does Recursion Pharmaceuticals Inc allow for Work Councils/Collective Agreements to be formed?
Has Recursion Pharmaceuticals Inc issued a profit warning in the past 24 months?
Does Recursion Pharmaceuticals Inc disclose parental leave metrics?
Does Recursion Pharmaceuticals Inc disclose climate scenario or pathway analysis?
Does Recursion Pharmaceuticals Inc disclose current and / or historical scope 1 emissions?
Are Operating Expesnses linked to emissions reduction?
Does Recursion Pharmaceuticals Inc disclose the pay ratio of women to men?
Does Recursion Pharmaceuticals Inc support suppliers with sustainability related research and development?
Does Recursion Pharmaceuticals Inc disclose the number of operations that have been subject to human rights reviews or human rights impact assessments?
Does Recursion Pharmaceuticals Inc reflect climate-related risks in its financial statements?
Is there a statment that there is no plan to expand their carbon intensite energy assets? (for example: 'We have no current plans to carry out further drilling for oil,')
Is Recursion Pharmaceuticals Inc involved in embryonic stem cell research?
Does Recursion Pharmaceuticals Inc disclose GHG and Air Emissions intensity?
Does Recursion Pharmaceuticals Inc disclose its waste policy?
Does Recursion Pharmaceuticals Inc report according to TCFD requirements?
Does Recursion Pharmaceuticals Inc disclose its policies for bribery, corruption, whistle-blower, conflict of interest?
Does Recursion Pharmaceuticals Inc disclose energy use targets?
Does Recursion Pharmaceuticals Inc disclose its Renewable Energy targets?

Are emissions metrics verified by STBi?

Does Recursion Pharmaceuticals Inc have a policy relating to cyber security?
Have a different question?
Potential Risks for Recursion Pharmaceuticals Inc
These potential risks are based on the size, segment and geographies of the company.
Recursion Pharmaceuticals, Inc. operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase IIa clinical trial to treat cerebral cavernous malformation; REC-2282 for the treatment of neurofibromatosis type 2; REC-4881 to treat familial adenomatous polyposis; and REC-3599, which is in Phase I clinical trial to treat GM2 gangliosidosis. Its preclinical stage product includes REC-3964 to treat Clostridium difficile colitis; REC-64917 for the treat of neural or systemic inflammation; REC-65029 to treat HRD-negative ovarian cancer; REC-648918 to enhance anti-tumor immune; REC-2029 for the treatment of wnt-mutant hepatocellular carcinoma; REC-14221 to treat solid and hematological malignancies; and REC-64151 for the treatment of immune checkpoint resistance in KRAS/STK11 mutant non-small cell lung cancer. The company has collaboration and agreement with Bayer AG; the University of Utah Research Foundation; Ohio State Innovation Foundation; Chromaderm, Inc.; and Takeda Pharmaceutical Company Limited. Recursion Pharmaceuticals, Inc. was incorporated in 2013 and is headquartered in Salt Lake City, Utah.